Compare ASNS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASNS | MYNZ |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 8.8M |
| IPO Year | 2022 | 2021 |
| Metric | ASNS | MYNZ |
|---|---|---|
| Price | $0.56 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $14.00 |
| AVG Volume (30 Days) | ★ 2.1M | 188.9K |
| Earning Date | 11-14-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,367,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $208.63 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.92 |
| 52 Week High | $17.80 | $8.20 |
| Indicator | ASNS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.02 | 54.02 |
| Support Level | $2.55 | $1.00 |
| Resistance Level | $3.10 | $1.15 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | -0.35 | 0.03 |
| Stochastic Oscillator | 2.49 | 76.27 |
Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.